BlossomHill Therapeutics, Inc. (BLSM)

NASDAQ: BLSM · Real-Time Price · USD

13.94

-1.04 (-6.94%)

Oct 16, 2026, 4:00 PM EDT - Market closed

BlossomHill Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	9.95	7.89	4.59
Research & Development	75.29	56.14	31.81
Operating Expenses	85.24	64.02	36.4
Operating Income	-85.24	-64.02	-36.4
Interest & Investment Income	3.66	3.48	5.71
Currency Exchange Gain (Loss)	-0.02	-0.01	-
Pretax Income	-81.6	-60.56	-30.7
Net Income	-81.6	-60.56	-30.7
Net Income to Common	-81.6	-60.56	-30.7
Net Income Growth	-	-	-
Shares Outstanding (Basic)	3	2	2
Shares Outstanding (Diluted)	3	2	2
Shares Change	-	6.47%	-
EPS (Basic)	-31.83	-24.83	-13.40
EPS (Diluted)	-31.83	-24.83	-13.40
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-71.06	-47.99	-31.51
Free Cash Flow Per Share	-27.72	-19.68	-13.76
EBITDA	-84.74	-63.58	-36.05
D&A For EBITDA	0.5	0.44	0.35
EBIT	-85.24	-64.02	-36.4

SEC Filings: 10-K · 10-Q